Results 271 to 280 of about 589,865 (354)

Long-Term Outcomes of Consolidative Proton Therapy for Pediatric Classical Hodgkin Lymphoma. [PDF]

Int J Part Ther
Martir-Vargas D, Indelicato DJ, Bechtel A, Bansal M, Milner J, Dean JB, Morris CG, Mendenhall NP, Mailhot Vega RB.   +8 more
europepmc   +1 more source

Characterization of cancer‐associated fibroblasts and their spatial architecture reveals heterogeneity and survival associations in classic Hodgkin lymphoma

Suvi‐Katri Leivonen, Kristiina Karihtala, Teijo Pellinen, Marja‐Liisa Karjalainen‐Lindsberg, Tomohiro Aoki, Christian Steidl, Sirpa Leppä   +6 more
openalex   +1 more source

Laktatazidose bei einer Patientin mit hochmalignem Non-Hodgkin-Lymphom Diffuse Large B-Cell-Lymphoma gemäss R.E.A.L.

, 2001
M Wendel, M Weiss, U Müller
openalex   +1 more source

Prognostic Value of Massiveness Parameters Measured on Baseline FDG PET in Advanced-Stage Hodgkin Lymphoma. [PDF]

Cancer Med
Draye-Carbonnier S, Mihailescu SD, Pinochet P, Texte E, Stamatoullas-Bastard A, Vera P, Becker S, Decazes P.   +7 more
europepmc   +1 more source

Beading wáwya: Counting coup on cancer

The Australian Journal of Anthropology, EarlyView.
Abstract In November of 2022, I was diagnosed with an aggressive form of breast cancer. After 26 years in remission, radiation treatments from my first cancer caused another one. In the months that followed my diagnosis, I gained a greater personal insight into both the medical field—their successes and shortcomings—and the power of creative processes ...
Gretchen Stolte
wiley   +1 more source

AI Improves Agreement and Reduces Time for Quantifying Metabolic Tumour Burden in Hodgkin Lymphoma. [PDF]

Hematol Rep
Sadik M, Barrington SF, Ulén J, Enqvist O, Trägårdh E, Saboury B, Lerberg Nielsen A, Loft A, Loaiza Gongora JL, Lopez Urdaneta J, Kumar R, van Essen M, Edenbrandt L.   +12 more
europepmc   +1 more source

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Journal of Clinical Oncology, 2012
A. Younes, A. Gopal, Scott E. Smith, S. Ansell, J. Rosenblatt, K. Savage, R. Ramchandren, N. Bartlett, B. Cheson, S. de Vos, A. Forero-Torres, C. Moskowitz, J. Connors, A. Engert, E. K. Larsen, D. Kennedy, E. Sievers, Robert Chen   +17 more
semanticscholar   +1 more source

Preemptive Rituximab for Epstein–Barr Virus Reactivation after Hematopoietic Cell Transplantation: Necessary for All?

Transplant Infectious Disease, EarlyView.
A sudden increase in EBV DNAemia appears to be a better predictor of PTLD and EBV end‐organ disease than persistent and stable levels of EBV DNAemia. Most HCT recipients with EBV DNAemia did not require rituximab, and immunosuppression reduction was sufficient to control most episodes of EBV reactivation.
Anna Beatriz Coelho de Souza, Anderson João Simione, Ana Cláudia Ferrari dos Santos, Iago Colturato, Fernanda Rodrigues Barbieri, Juliana Ribeiro do Prado Moreno, Lilian Perílio Zanetti, Leila Cibele Serra de Oliveira, Erika Rodrigues Pontes Delattre, Juliana Silva Santos, Mair Pedro de Souza, Vergílio A. R. Colturato, Clarisse M. Machado   +12 more
wiley   +1 more source

Individualized Breast Surveillance in a Young Hodgkin Lymphoma Survivor With High-Risk Features. [PDF]

Cureus
Kanter T.
europepmc   +1 more source

Impact of Treatment and Insurance on Socioeconomic Disparities in Survival after Adolescent and Young Adult Hodgkin Lymphoma: A Population-Based Study

Cancer Epidemiology, Biomarkers and Prevention, 2016
T. Keegan, Mindy C Derouen, H. Parsons, C. Clarke, Debbie E. Goldberg, C. Flowers, S. Glaser   +6 more
semanticscholar   +1 more source